FRAMINGHAM, Mass.--Genzyme Molecular Oncology announced that it has entered into an agreement with the Dana-Farber Cancer Institute that will give the company an option to exclusively license novel fusion cell technology developed by researchers at Dana-Farber. Genzyme Molecular also said it has initiated funding at the institute.
Genzyme Molecular plans to combine fusion cell technology--the subject of a study published last month in the Proceedings of the National Academy of Sciences--with proprietary technologies such as Serial Analysis of Gene Expres sion, and Solid Phase Epitope Recovery, in an integrated antigen discovery program. Genzyme Molecular develops gene-based approaches to cancer therapy and diagnosis and employs an integrated approach to translate information gained through its genomics capabilities into gene therapy, small molecule therapeutics, and genetic diagnostics. Genzyme Molecular Oncology is a division of biotechnology company Genzyme and has its own common stock, not yet publicly traded.